Comparative Study between the Effect of Dexmedetomidine versus Nalbuphine as an Adjuvant to Bupivacaine in Paravertebral Block in Breast Cancer Surger

Comparative Study between the Effect of Dexmedetomidine versus Nalbuphine as an Adjuvant to Bupivacaine in Paravertebral Block in Breast Cancer Surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201710002161189

Enrollment

Registered

2017-03-31

Start date

2016-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Surgery breast cancer

Interventions

Group PB: Bupivacaine only

Group PBD: Bupivacaine + Dexmeditomedine

Group PBN: Bupivacaine +Nalbuphine

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: ASA I, II, III female 18-78 breast cancer surgery

Exclusion criteria

Exclusion criteria: Exclusion criteria included patients undergoing bilateral breast surgery or breast reconstruction; those having contra-indications for PVB, e.g., patient refusal, infection at injection site, anticoagulant therapy, abnormal coagulation profile, or hypersensitivity to LA; patients on chronic antiemetics or chronic pain medication; pregnant patients; central neuropathy, liver or renal impairment, drug or alcohol abusers, and those with psychiatric illnesses that would interfere with perception and assessment of pain and obese patients with a body mass index (BMI) >30 kg/m2.

Design outcomes

Primary

Measure	Time frame
anelgesic consumption (tramadol)	—

Secondary

Measure	Time frame
pain scores ;, intraoperative fentanyl requirements;Time to first analgesic request (TFR), which was defined: time from completion of the paravertebral block injection till time of first analgesic request, ;complications;sedation scores	—

Countries

Egypt

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026